A recent population-based cohort study failed to show a decreased risk of pancreatic cancer through the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers36, even though such inhibitors have been shown to suppress pancreatic cancer growth in pre-clinical models35, 37, 38. This evidence concerns the gene ACE and pancreatic neoplasm.